The presence of PD-L1+ tumor-associated macrophages (TAMs) and PD-1+ TILs indicates that the pathway may be activated in 20–35% of cases where PD-1 is expressed on CD4+ and CD8+ T-lymphocytes upon antigen receptor signaling [41,43]. The gene discussed is CD8A; the disease is neoplasm.